6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Serum‐Free Medium Enhances the Immunosuppressive and Antifibrotic Abilities of Mesenchymal Stem Cells Utilized in Experimental Renal Fibrosis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Serum used in culture medium brings risks of immune reactions or infections and thus may hinder using ex vivo expanded mesenchymal stem cells (MSCs) for medical treatment. Here, we cultured MSCs in a serum‐free medium (SF‐MSCs) and in a medium containing 10% fetal bovine serum (10%MSCs) and investigated their effects on inflammation and fibrosis. MSC‐conditioned medium suppressed transforming growth factor‐β1–induced phosphorylation of Smad2 in HK‐2 cells, with no significant difference between the two MSCs. This finding suggests that the direct antifibrotic effect of SF‐MSCs is similar to that of 10%MSCs. However, immunohistochemistry revealed that renal fibrosis induced by unilateral ureteral obstruction in rats was more significantly ameliorated by the administration of SF‐MSCs than by that of 10%MSCs. Coculture of MSCs and monocytic THP‐1 cell‐derived macrophages using a Transwell system showed that SF‐MSCs significantly induced polarization from the proinflammatory M1 to the immunosuppressive M2 phenotype macrophages, suggesting that SF‐MSCs strongly suppress the persistence of inflammation. Furthermore, the gene expression of tumor necrosis factor‐α–induced protein 6 (TSG‐6), which inhibits the recruitment of inflammatory cells, was higher in SF‐MSCs than in 10%MSCs, and TSG‐6 knockdown in SF‐MSCs attenuated the anti‐inflammatory responses in unilateral ureteral obstruction rats. These findings imply that SF culture conditions can enhance the immunosuppressive and antifibrotic abilities of MSCs and the administration of ex vivo expanded SF‐MSCs has the potential to be a useful therapy for preventing the progression of renal fibrosis. S tem C ells T ranslational M edicine 2018;7:893–905

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases.

          Fibroproliferative diseases, including the pulmonary fibroses, systemic sclerosis, liver cirrhosis, cardiovascular disease, progressive kidney disease, and macular degeneration, are a leading cause of morbidity and mortality and can affect all tissues and organ systems. Fibrotic tissue remodeling can also influence cancer metastasis and accelerate chronic graft rejection in transplant recipients. Nevertheless, despite its enormous impact on human health, there are currently no approved treatments that directly target the mechanism(s) of fibrosis. The primary goals of this Review series on fibrotic diseases are to discuss some of the major fibroproliferative diseases and to identify the common and unique mechanisms of fibrogenesis that might be exploited in the development of effective antifibrotic therapies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Mechanisms of tubulointerstitial fibrosis.

            The pathologic paradigm for renal progression is advancing tubulointerstitial fibrosis. Whereas mechanisms underlying fibrogenesis have grown in scope and understanding in recent decades, effective human treatment to directly halt or even reverse fibrosis remains elusive. Here, we examine key features mediating the molecular and cellular basis of tubulointerstitial fibrosis and highlight new insights that may lead to novel therapies. How to prevent chronic kidney disease from progressing to renal failure awaits even deeper biochemical understanding.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages.

              Mesenchymal stem cells (MSCs) are capable of modulating the immune system through interaction with a wide range of immune cells. This study investigates the hypothesis that interaction of MSCs with macrophages could play a significant role in their antiinflammatory/immune modulatory effects. MSCs were derived from bone marrow and monocytes were isolated from peripheral blood of healthy donors. We cultured human monocytes for 7 days without any added cytokines to generate macrophages, and then cocultured them for 3 more days with culture-expanded MSCs. We used cell surface antigen expression and intracellular cytokine expression patterns to study the immunophenotype of macrophages at the end of this coculture period, and phagocytic assays to investigate their functional activity in vitro. Macrophages cocultured with MSCs consistently showed high-level expression of CD206, a marker of alternatively activated macrophages. Furthermore, these macrophages expressed high levels of interleukin (IL)-10 and low levels of IL-12, as determined by intracellular staining, typical of alternatively activated macrophages. However, macrophages cocultured with MSCs also expressed high levels of IL-6 and low levels of tumor necrosis factor-alpha (TNF-alpha) compared to controls. Functionally, macrophages cocultured with MSCs showed a higher level of phagocytic activity. We describe a novel type of human macrophage generated in vitro after coculture with MSCs that assumes an immunophenotype defined as IL-10-high, IL-12-low, IL-6-high, and TNF-alpha-low secreting cells. These MSC-educated macrophages may be a unique and novel type of alternatively activated macrophage with a potentially significant role in tissue repair.
                Bookmark

                Author and article information

                Contributors
                ayumu@hiroshima-u.ac.jp
                masakit@hiroshima-u.ac.jp
                Journal
                Stem Cells Transl Med
                Stem Cells Transl Med
                10.1002/(ISSN)2157-6580
                SCT3
                Stem Cells Translational Medicine
                John Wiley and Sons Inc. (Hoboken )
                2157-6564
                2157-6580
                30 September 2018
                December 2018
                : 7
                : 12 ( doiID: 10.1002/sct3.2018.7.issue-12 )
                : 893-905
                Affiliations
                [ 1 ] Department of Nephrology Hiroshima University Hospital Hiroshima Japan
                [ 2 ] Department of Stem Cell Biology and Medicine Graduate School of Biomedical & Health Sciences, Hiroshima University Hiroshima Japan
                [ 3 ] Department of Cardiovascular Regeneration and Medicine Research Institute for Radiation Biology and Medicine, Hiroshima University Hiroshima Japan
                [ 4 ] Natural Science Center for Basic Research and Development Hiroshima University Hiroshima Japan
                [ 5 ] TWOCELLS Company, Limited Hiroshima Japan
                [ 6 ] Division of Regeneration and Medicine Medical Center for Translational and Clinical Research, Hiroshima University Hospital Hiroshima Japan
                Author notes
                [*] [* ]Correspondence: Ayumu Nakashima, M.D., Ph.D., Department of Stem Cell Biology and Medicine, Graduate School of Biomedical & Sciences, Hiroshima University, 1‐2‐3 Kasumi, Minami‐ku, Hiroshima, Hiroshima 734‐8553, Japan. Telephone: 81‐82‐257‐1987; e‐mail: ayumu@ 123456hiroshima-u.ac.jp ; or Takao Masaki, M.D., Ph.D., Department of Nephrology, Hiroshima University Hospital, 1‐2‐3 Kasumi, Minami‐ku, Hiroshima, Hiroshima 734‐8551, Japan. Telephone: 81‐82‐257‐1506; e‐mail: masakit@ 123456hiroshima-u.ac.jp
                Author information
                https://orcid.org/0000-0002-7838-1494
                Article
                SCT312410
                10.1002/sctm.17-0284
                6265641
                30269426
                18fa491d-3603-4bfe-aaeb-cfe72884e7aa
                © 2018 The Authors. stem cells translational medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 05 December 2017
                : 25 August 2018
                Page count
                Figures: 8, Tables: 0, Pages: 14, Words: 9971
                Funding
                Funded by: JSPS KAKENHI
                Award ID: JP17K09699
                Award ID: JP26461229
                Categories
                Enabling Technologies for Cell‐Based Clinical Translation
                Translational Research Articles and Reviews
                Enabling Technologies for Cell‐Based Clinical Translation
                Custom metadata
                2.0
                sct312410
                December 2018
                Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.5.3 mode:remove_FC converted:30.11.2018

                mesenchymal stem cells,serum‐free culture condition,immunosuppression,tumor necrosis factor‐α–induced protein 6,renal fibrosis

                Comments

                Comment on this article